WO2013156936A1 - Process for the preparation of rivaroxaban and intermediates thereof - Google Patents

Process for the preparation of rivaroxaban and intermediates thereof Download PDF

Info

Publication number
WO2013156936A1
WO2013156936A1 PCT/IB2013/053025 IB2013053025W WO2013156936A1 WO 2013156936 A1 WO2013156936 A1 WO 2013156936A1 IB 2013053025 W IB2013053025 W IB 2013053025W WO 2013156936 A1 WO2013156936 A1 WO 2013156936A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
rivaroxaban
preparation
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/053025
Other languages
French (fr)
Inventor
Pankaj Kumar Singh
Mohammed Salman Hashmi
Yoginder Pal Sachdeva
Chandra Has Khanduri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to SG11201406623PA priority Critical patent/SG11201406623PA/en
Priority to AU2013250801A priority patent/AU2013250801A1/en
Priority to US14/394,547 priority patent/US20150299160A1/en
Priority to EP13726292.9A priority patent/EP2838897A1/en
Priority to IN9450DEN2014 priority patent/IN2014DN09450A/en
Publication of WO2013156936A1 publication Critical patent/WO2013156936A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention provides processes for the preparation of rivaroxaban and its intermediates.
  • Rivaroxaban chemically is 5-chloro-N-( ⁇ (5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl] - 1 ,3-oxazolidin-5- l ⁇ methyl)thiophene-2-carboxamide of Formula I.
  • Rivaroxaban is used as an anti-thrombotic agent.
  • U.S. Patent No. 7,157,456 provides rivaroxaban and processes for its preparation.
  • U.S. Patent No. 8,106,192 provides a process for the preparation of N-((S)-3- bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide, wherein (2S)-3- aminopropane- 1 ,2-diol hydrochloride is reacted with 5-chlorothiophene-2-carbonyl chloride to provide N-((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide.
  • U.S. Publication No. 2010/0273789 provides a process for the preparation of 5- chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide, wherein ((S)-3-bromo-2- hydroxypropyl)-5-chlorothiophene-2-carboxamide (50 g, 0.167 moles) is stirred with potassium carbonate (155 g, 1.12 moles) in the presence of anhydrous tetrahydrofuran (500 mL) for three days at room temperature to give 5-chloro-N-[(2S)-oxiran-2- ylmethyl]thiophene-2-carboxamide.
  • 2007/0066615 provides a process for the preparation of 5- chloro-N-((2R)-2-hydroxy-3- ⁇ [4-(3-oxo-4-morpholinyl)-phenyl]amino ⁇ propyl)-2- thiophenecarboxamide, wherein a solution of 4-(4-aminophenyl)morpholin-3-one (2.6 mmol) and 5-chloro-N-[(2S)-oxiranylmethyl]-2-thiophenecarboxamide (3.1 mmol) in tetrahydrofuran is stirred overnight at 60°C in the presence of ytterbium(III)
  • U.S. Publication No. 2010/0120718 provides a general method for preparing substituted N-(3-amino-2-hydroxypropyl)-5-chloro-2-thiophenecarboxamide derivatives, wherein 5-chloro-N-(2-oxiranylmethyl)-2-thiophenecarboxamide (1.0 equivalent) is stirred for 2 hours to 6 hours with a primary amine or aniline derivative (1.5 equivalents to 2.5 equivalents) in the presence of a solvent at room temperature or at temperatures up to 80°C.
  • the product can be isolated from the reaction mixture by chromatography.
  • PCT Publication No. WO 2012/092873 provides a process for the preparation of rivaroxaban, wherein 5-chloro-N-[(2S)-3-chloro-2-hydroxypropyl]thiophene-2- carboxamide or 5-chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide is treated with substituted or unsubstituted phenyl methyl[4(3-oxo-morpholin-4-yl)phenyl] carbamate.
  • the present inventors have developed simple, safe, efficient, economical, industrially feasible processes that provide rivaroxaban and its intermediates in good yield.
  • the present invention provides processes for the preparation of rivaroxaban and its intermediates. Detailed Description of the Invention
  • the present invention provides processes for the preparation of rivaroxaban and its intermediates.
  • a first aspect of the present invention provides a process for the preparation of 5- chloro-N-[(2S)-3-chloro-2-h droxypropyl]thiophene-2-carboxamide of Formula II
  • a second aspect of the present invention provides a process for the preparation of 5-chloro-N-[(2S)-3-chloro-2-h droxypropyl]thiophene-2-carboxamide of Formula II,
  • R is CI, Br, or I, to obtain the compound of Formula II.
  • a third aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • a fourth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • R is CI, Br, or I, to obtain a com ound of Formula II;
  • a fifth aspect of the present invention provides a process for the preparation of a compound of Formula V,
  • a sixth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • a seventh aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • R is CI, Br, or I, to obtain a compound of Formula II;
  • An eighth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • a ninth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
  • R is CI, Br, or I, to obtain a com ound of Formula II;
  • a tenth aspect of the resent invention provides a compound of Formula II.
  • An eleventh aspect of the present invention provides use of the compound of Formula II
  • the compound of Formula III or salts thereof, the reactive derivative of the compound of Formula IV, or the compound of Formula IVa may be prepared by any method provided in the art, for example, the methods described in U.S. Patent No.
  • the salt of the compound of Formula III for example the hydrochloride salt of the compound of Formula III, may also be prepared as described herein.
  • the compound of Formula III is treated with the reactive derivative of the compound of Formula IV, for example, 5- chlorothiophene-2-carbonyl chloride, to obtain the compound of Formula II in a solvent.
  • the reactive derivative of the compound of Formula IV may be reacted with the compound of Formula III after isolation from the reaction mixture in which it is formed, or the reaction mixture containing the reactive derivative of the compound of Formula IV can also be used for the reaction with the compound of Formula III.
  • the reactive derivative of the compound of Formula IV is reacted with the compound of Formula III in the presence of a base.
  • the base may be, for example, sodium bicarbonate.
  • a salt of the compound of Formula III such as the hydrochloride salt
  • it may be treated with a base such as sodium bicarbonate prior to the reaction with the compound of Formula IV.
  • the molar ratio of the base and the salt of a compound of Formula III may range from about 1 : 1 to about 4: 1.
  • the solvent should not interfere with the reaction, and can be selected from the group comprising tetrahydrofuran, toluene, dichloromethane, ethyl acetate, or mixtures thereof.
  • the compound of Formula III is treated with the compound of Formula IV in the solvent at about 0°C to about 35°C.
  • the resulting mixture is stirred for about 1 hour to about 8 hours at about 0°C to about 35°C.
  • the compound of Formula II may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
  • the compound of Formula II can be converted into rivaroxaban of Formula I by following the processes mentioned herein, or processes provided in prior art, for example, U.S. Patent No. 8,106,192.
  • the compound of Formula II is treated with base in solvent to obtain the compound of Formula V.
  • the solvent may be 1 ,4-dioxane, methanol, ethanol, or their mixtures with water.
  • the base may be sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide, potassium hydroxide, or mixtures thereof.
  • the base may be used as a solid or in solution.
  • the compound of Formula II is treated with the base at about 0°C to about 30°C.
  • the mixture is stirred for about 1 hour to about 8 hours at about 0°C to about 30°C.
  • the product may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof.
  • the compound of Formula V is treated with the compound of Formula VI in a solvent to obtain the compound of Formula VII.
  • the solvent may be ethanol, methanol, tetrahydrofuran, or their mixtures with water.
  • the mixture containing the compound of Formula V and the compound of Formula VI is heated to reflux for about 0.5 hours to about 6 hours.
  • the reaction mass is cooled to a temperature of about 0°C to about 35°C and stirred for about 0.5 hours to about 4 hours at about 0°C to about 35°C.
  • the compound of Formula VII may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
  • the compound of Formula VII is treated with 1 , 1 -carbonyldiimidazole in a solvent.
  • the solvent may be dichloromethane.
  • the mixture is stirred for about 2 hours to about 6 hours at about 25°C to about 30°C.
  • the compound of Formula I may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
  • the compound of Formula V can also be converted into rivaroxaban of
  • the salt of a compound of Formula III in the present invention includes, for example, hydrochloride salts, hydrobromide salts, sulfate salts, nitrate salts, phosphate salts, formate salts, acetate salts, trifluoroacetate salts, methanesulfonate salts, and p- toluenesulfonate salts.
  • the reactive derivative of a compound of Formula IV in the present invention includes acid halides, acid azides, acid anhydrides, mixed acid anhydrides, active amides, active esters, and active thio esters.
  • Examples of reactive derivatives include acid chloride, acid amide of a free acid, di-ethoxyphosphoric acid ester, p-nitrophenyl ester, cyanomethyl ester, pentachlorophenyl ester, N-hydroxysuccinimide ester, imidazolyl ester, N-hydroxy phthalimide ester, 1 -hydroxybenzotriazole ester, 6-chloro- 1 - hydroxybenzotriazole ester, 1 -hydroxy- lH-2-pyridone ester, 2-pyridylthiol ester, and 2- benzothiazolylthiol ester.
  • ambient temperature refers to a temperature in the range of O°C to 35°C.
  • Example 1 Preparation of (2S)-l-amino-3-chloropropan-2-ol hydrochloride (Formula III) A solution of benzaldehyde (50 g, 0.540 moles) in ethanol (100 mL) was cooled to 15°C, and aqueous ammonia (25%, 57.4 mL) was added drop wise over 15 minutes to 20 minutes. Ethanol (25 mL) was added to the mixture. The mixture was stirred at 15°C to 20°C for 15 minutes to 20 minutes. (S)-Epichlorohydrin (50 g, 0.540 moles) and ethanol (50 mL) were added.
  • the reaction mixture was allowed to warm to 40°C and stirred for 1 hour at 15°C to 40°C.
  • the reaction mixture was again stirred at 35°C to 40°C for 6 hours, cooled to 25°C to 30°C, and further stirred for 12 hours.
  • the solution was concentrated to dryness under vacuum at 50°C to 55°C.
  • Ethanol 50 mL was added to the oil obtained, and the mixture was concentrated under vacuum at 50°C to 55°C.
  • Toluene 125 mL was added to the oil obtained, and the mixture was heated to 35°C to 40°C.
  • Aqueous hydrochloric acid (6.8 N, 129.5 mL) was added to the solution at 35°C to 40°C and stirred for 2 hours.
  • the reaction mass was cooled to 25°C to 30°C, and the aqueous layer was separated.
  • the organic layer was extracted with water (50 mL).
  • the combined aqueous layers were concentrated under vacuum at 70°C to 75°C to get a semisolid material.
  • the semisolid material was charged with ethanol (25 mL) and heated to 60°C to 65°C to get a clear solution.
  • the solution was first cooled to 25°C to 30°C and then to -20°C.
  • the slurry obtained was stirred for 1 hour at -20°C.
  • the slurry was filtered and suck dried.
  • the wet solid was dried at 45°C to 50°C under vacuum.
  • the suspension was heated to 45°C to 50°C and stirred at 45°C to 50°C for 15 minutes.
  • the mixture was cooled to 25°C to 30°C, and stirred at 25°C to 30°C for 2 hours.
  • the slurry obtained was filtered, washed with toluene (10 mL), and the wet solid was dried at 50°C to 55°C under vacuum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

PROCESS FOR THE PREPARATION OF RIVAROXABAN AND ITS
INTERMEDIATES
Field of the Invention
The present invention provides processes for the preparation of rivaroxaban and its intermediates.
Background of the Invention
Rivaroxaban chemically is 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl] - 1 ,3-oxazolidin-5- l}methyl)thiophene-2-carboxamide of Formula I.
Figure imgf000002_0001
Formula I
Rivaroxaban is used as an anti-thrombotic agent.
U.S. Patent No. 7,157,456 provides rivaroxaban and processes for its preparation.
U.S. Patent No. 8,106,192 provides a process for the preparation of N-((S)-3- bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide, wherein (2S)-3- aminopropane- 1 ,2-diol hydrochloride is reacted with 5-chlorothiophene-2-carbonyl chloride to provide N-((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide. The resulting compound is treated with hydrobromic acid in the presence of acetic anhydride at 60°C to 65°C, and the reaction mixture is stirred overnight to give N-((S)-3-bromo-2- hydroxypropyl)-5-chlorothiophene-2-carboxamide, which is further converted into rivaroxaban.
U.S. Publication No. 2010/0273789 provides a process for the preparation of 5- chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide, wherein ((S)-3-bromo-2- hydroxypropyl)-5-chlorothiophene-2-carboxamide (50 g, 0.167 moles) is stirred with potassium carbonate (155 g, 1.12 moles) in the presence of anhydrous tetrahydrofuran (500 mL) for three days at room temperature to give 5-chloro-N-[(2S)-oxiran-2- ylmethyl]thiophene-2-carboxamide. U.S. Publication No. 2007/0066615 provides a process for the preparation of 5- chloro-N-((2R)-2-hydroxy-3- {[4-(3-oxo-4-morpholinyl)-phenyl]amino}propyl)-2- thiophenecarboxamide, wherein a solution of 4-(4-aminophenyl)morpholin-3-one (2.6 mmol) and 5-chloro-N-[(2S)-oxiranylmethyl]-2-thiophenecarboxamide (3.1 mmol) in tetrahydrofuran is stirred overnight at 60°C in the presence of ytterbium(III)
trifluoromethanesulfonate to give a precipitate, which is filtered off to provide the product in 54% yield. The remaining filtrate is concentrated and the residue obtained is purified by preparative HPLC to provide further 38% of the product.
U.S. Publication No. 2010/0120718 provides a general method for preparing substituted N-(3-amino-2-hydroxypropyl)-5-chloro-2-thiophenecarboxamide derivatives, wherein 5-chloro-N-(2-oxiranylmethyl)-2-thiophenecarboxamide (1.0 equivalent) is stirred for 2 hours to 6 hours with a primary amine or aniline derivative (1.5 equivalents to 2.5 equivalents) in the presence of a solvent at room temperature or at temperatures up to 80°C. The product can be isolated from the reaction mixture by chromatography.
PCT Publication No. WO 2012/092873 provides a process for the preparation of rivaroxaban, wherein 5-chloro-N-[(2S)-3-chloro-2-hydroxypropyl]thiophene-2- carboxamide or 5-chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide is treated with substituted or unsubstituted phenyl methyl[4(3-oxo-morpholin-4-yl)phenyl] carbamate.
The prior art processes for the preparation of rivaroxaban and/or its intermediates involve long reaction times, make use of corrosive hydrobromic acid, and use expensive starting materials, catalysts, and chromatography. These processes generate corrosive hydrobromic acid as a by-product and provide products in lower yield. Accordingly, these processes are not suitable on an industrial scale.
The present inventors have developed simple, safe, efficient, economical, industrially feasible processes that provide rivaroxaban and its intermediates in good yield.
Summary of the Invention
The present invention provides processes for the preparation of rivaroxaban and its intermediates. Detailed Description of the Invention
The present invention provides processes for the preparation of rivaroxaban and its intermediates.
A first aspect of the present invention provides a process for the preparation of 5- chloro-N-[(2S)-3-chloro-2-h droxypropyl]thiophene-2-carboxamide of Formula II
Figure imgf000004_0001
Formula II
wherein the process comprises treatin a compound of Formula III
Figure imgf000004_0002
Formula III
a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000004_0003
Formula IV
to obtain the compound of Formula II.
A second aspect of the present invention provides a process for the preparation of 5-chloro-N-[(2S)-3-chloro-2-h droxypropyl]thiophene-2-carboxamide of Formula II,
Figure imgf000004_0004
Formula II
wherein the process comprises treatin a compound of Formula III
Figure imgf000004_0005
Formula III or a salt thereof with a compound of Formula IVa
Figure imgf000005_0001
Formula IVa
wherein R is CI, Br, or I, to obtain the compound of Formula II.
A third aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000005_0002
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000005_0003
Formula III
a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000005_0004
Formula IV
to obtain a com ound of Formula II; and
Figure imgf000005_0005
Formula II
b) converting the compound of Formula II into rivaroxaban. A fourth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000006_0001
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000006_0002
Formula III
or a salt thereof with a compound of Formula IVa
Figure imgf000006_0003
Formula IVa
wherein R is CI, Br, or I, to obtain a com ound of Formula II; and
Figure imgf000006_0004
Formula II
b) converting the compound of Formula II into rivaroxaban. A fifth aspect of the present invention provides a process for the preparation of a compound of Formula V,
Figure imgf000007_0001
Formula V
wherein the process comprises treatin a compound of Formula II
Figure imgf000007_0002
Formula II
with a base to obtain the compound of Formula V.
A sixth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000007_0003
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000007_0004
Formula III or a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000008_0001
Formula IV
to obtain a compound of Formula II;
Figure imgf000008_0002
Formula II
b) treating the compound of Formula II
Figure imgf000008_0003
Formula II
with a base to obtain a compound of Formula V; and
Figure imgf000008_0004
Formula V
c) converting the compound of Formula V into rivaroxaban.
A seventh aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000008_0005
Formula I wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000009_0001
Formula III
a salt thereof with a compound of Formula IVa
Figure imgf000009_0002
Formula IVa
wherein R is CI, Br, or I, to obtain a compound of Formula II;
Figure imgf000009_0003
Formula II
b) treating the com ound of Formula II
Figure imgf000009_0004
Formula II
with a base to obtain a compound of Formula V; and
Figure imgf000009_0005
c) converting the compound of Formula V into rivaroxaban. An eighth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000010_0001
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000010_0002
Formula III
a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000010_0003
Formula IV
to obtain a com ound of Formula II;
Figure imgf000010_0004
Formula II
b) treating the com ound of Formula II
Figure imgf000010_0005
Formula II
with a base to obtain a compound of Formula V;
Figure imgf000011_0001
Formula V
c) treating the compound of Formula V
Figure imgf000011_0002
Formula VI
to obtain a compound of Formula VII; and
Figure imgf000011_0003
Formula VII
d) converting the compound of Formula VII into rivaroxaban.
A ninth aspect of the present invention provides a process for the preparation of rivaroxaban of Formula I,
Figure imgf000011_0004
Formula I wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000012_0001
Formula III
a salt thereof with a compound of Formula IVa
Figure imgf000012_0002
Formula IVa
wherein R is CI, Br, or I, to obtain a com ound of Formula II;
Figure imgf000012_0003
Formula II
b) treating the com ound of Formula II
Figure imgf000012_0004
Formula II
with a base to obtain a compound of Formula V;
Figure imgf000012_0005
c) treating the compound of Formula V
Figure imgf000013_0001
Formula V
with a compound of Formula VI
Figure imgf000013_0002
Formula VI
to obtain a compound of Formula VII; and
Figure imgf000013_0003
Formula VII
d) converting the compound of Formula VII into rivaroxaban.
A tenth aspect of the resent invention provides a compound of Formula II.
Figure imgf000013_0004
Formula II
An eleventh aspect of the present invention provides use of the compound of Formula II
Figure imgf000013_0005
Formula II for the preparation of rivaroxaban.
The compound of Formula III or salts thereof, the reactive derivative of the compound of Formula IV, or the compound of Formula IVa, may be prepared by any method provided in the art, for example, the methods described in U.S. Patent No.
7, 157,456, U.S. Patent No. 6,107,519, or any analogous method. The salt of the compound of Formula III, for example the hydrochloride salt of the compound of Formula III, may also be prepared as described herein. The compound of Formula III is treated with the reactive derivative of the compound of Formula IV, for example, 5- chlorothiophene-2-carbonyl chloride, to obtain the compound of Formula II in a solvent. The reactive derivative of the compound of Formula IV may be reacted with the compound of Formula III after isolation from the reaction mixture in which it is formed, or the reaction mixture containing the reactive derivative of the compound of Formula IV can also be used for the reaction with the compound of Formula III. The reactive derivative of the compound of Formula IV is reacted with the compound of Formula III in the presence of a base. The base may be, for example, sodium bicarbonate. When a salt of the compound of Formula III, such as the hydrochloride salt is used, it may be treated with a base such as sodium bicarbonate prior to the reaction with the compound of Formula IV. The molar ratio of the base and the salt of a compound of Formula III may range from about 1 : 1 to about 4: 1. The solvent should not interfere with the reaction, and can be selected from the group comprising tetrahydrofuran, toluene, dichloromethane, ethyl acetate, or mixtures thereof. The compound of Formula III is treated with the compound of Formula IV in the solvent at about 0°C to about 35°C. The resulting mixture is stirred for about 1 hour to about 8 hours at about 0°C to about 35°C. The compound of Formula II may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
Further, the compound of Formula II can be converted into rivaroxaban of Formula I by following the processes mentioned herein, or processes provided in prior art, for example, U.S. Patent No. 8,106,192.
The compound of Formula II is treated with base in solvent to obtain the compound of Formula V. The solvent may be 1 ,4-dioxane, methanol, ethanol, or their mixtures with water. The base may be sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide, potassium hydroxide, or mixtures thereof. The base may be used as a solid or in solution. The compound of Formula II is treated with the base at about 0°C to about 30°C. The mixture is stirred for about 1 hour to about 8 hours at about 0°C to about 30°C. The product may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof.
The compound of Formula V is treated with the compound of Formula VI in a solvent to obtain the compound of Formula VII. The solvent may be ethanol, methanol, tetrahydrofuran, or their mixtures with water. The mixture containing the compound of Formula V and the compound of Formula VI is heated to reflux for about 0.5 hours to about 6 hours. The reaction mass is cooled to a temperature of about 0°C to about 35°C and stirred for about 0.5 hours to about 4 hours at about 0°C to about 35°C. The compound of Formula VII may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
The compound of Formula VII is treated with 1 , 1 -carbonyldiimidazole in a solvent. The solvent may be dichloromethane. The mixture is stirred for about 2 hours to about 6 hours at about 25°C to about 30°C. The compound of Formula I may be isolated from the mixture by methods including concentration, distillation, decantation, filtration, evaporation, centrifugation, or a combination thereof, and may further be dried.
Further, the compound of Formula V can also be converted into rivaroxaban of
Formula I by the processes provided in prior art, for example, PCT Publication No. WO 201 1/098501 or U.S. Patent No. 8,106,192.
The salt of a compound of Formula III in the present invention includes, for example, hydrochloride salts, hydrobromide salts, sulfate salts, nitrate salts, phosphate salts, formate salts, acetate salts, trifluoroacetate salts, methanesulfonate salts, and p- toluenesulfonate salts.
The reactive derivative of a compound of Formula IV in the present invention includes acid halides, acid azides, acid anhydrides, mixed acid anhydrides, active amides, active esters, and active thio esters. Examples of reactive derivatives include acid chloride, acid amide of a free acid, di-ethoxyphosphoric acid ester, p-nitrophenyl ester, cyanomethyl ester, pentachlorophenyl ester, N-hydroxysuccinimide ester, imidazolyl ester, N-hydroxy phthalimide ester, 1 -hydroxybenzotriazole ester, 6-chloro- 1 - hydroxybenzotriazole ester, 1 -hydroxy- lH-2-pyridone ester, 2-pyridylthiol ester, and 2- benzothiazolylthiol ester.
The term "about", as used herein, when used along with values assigned to certain measurements and parameters means a variation of up to 10% from such values, or in case of a range of values, means up to a 10% variation from both the lower and upper limits of such ranges.
The term "ambient temperature", as used herein, refers to a temperature in the range of O°C to 35°C.
While the present invention has been described in terms of its specific
embodiments, certain modifications and equivalents will be apparent to those skilled in the art, and are intended to be included within the scope of the present invention.
EXAMPLES
Example 1 : Preparation of (2S)-l-amino-3-chloropropan-2-ol hydrochloride (Formula III) A solution of benzaldehyde (50 g, 0.540 moles) in ethanol (100 mL) was cooled to 15°C, and aqueous ammonia (25%, 57.4 mL) was added drop wise over 15 minutes to 20 minutes. Ethanol (25 mL) was added to the mixture. The mixture was stirred at 15°C to 20°C for 15 minutes to 20 minutes. (S)-Epichlorohydrin (50 g, 0.540 moles) and ethanol (50 mL) were added. The reaction mixture was allowed to warm to 40°C and stirred for 1 hour at 15°C to 40°C. The reaction mixture was again stirred at 35°C to 40°C for 6 hours, cooled to 25°C to 30°C, and further stirred for 12 hours. The solution was concentrated to dryness under vacuum at 50°C to 55°C. Ethanol (50 mL) was added to the oil obtained, and the mixture was concentrated under vacuum at 50°C to 55°C. Toluene (125 mL) was added to the oil obtained, and the mixture was heated to 35°C to 40°C. Aqueous hydrochloric acid (6.8 N, 129.5 mL) was added to the solution at 35°C to 40°C and stirred for 2 hours. The reaction mass was cooled to 25°C to 30°C, and the aqueous layer was separated. The organic layer was extracted with water (50 mL). The combined aqueous layers were concentrated under vacuum at 70°C to 75°C to get a semisolid material. The semisolid material was charged with ethanol (25 mL) and heated to 60°C to 65°C to get a clear solution. The solution was first cooled to 25°C to 30°C and then to -20°C. The slurry obtained was stirred for 1 hour at -20°C. The slurry was filtered and suck dried. The wet solid was dried at 45°C to 50°C under vacuum.
Yield = 31.5 g (50%) Example 2: Preparation of 5-chloro-N (2S)-3-chloro-2-hvdroxypropyl1thiophene-2- carboxamide (Formula II)
Sodium bicarbonate (1 1.1 g, 0.132 moles) was added to a solution of (2S)- 1 - amino-3-chloropropan-2-ol hydrochloride (Formula III - 15 g, 0.102 moles) in tetrahydrofuran (45 mL) and deionized water (90 mL) at ambient temperature. The mixture was stirred at 25°C to 30°C for 10 minutes to 15 minutes. The mixture was cooled to 15°C and a solution of 5-chlorothiophene-2-carbonyl chloride (a reactive derivative of Formula IV, or Formula IVa, wherein R = CI) (24 g, 0.132 moles) in toluene (22.5 mL) was added at 10°C to 15°C over 30 minutes to 35 minutes. The mixture was stirred at 10°C to 15°C for 2 hours, and the reaction mass was heated to 25°C to 30°C. The organic layer was separated, and the aqueous layer was extracted with toluene (45 mL). The combined organic layers were concentrated in vacuum at 45°C to 50°C to get a brown colored solid. The solid was suspended in toluene (75 mL). The suspension was heated to 45°C to 50°C and stirred at 45°C to 50°C for 15 minutes. The mixture was cooled to 25°C to 30°C, and stirred at 25°C to 30°C for 2 hours. The slurry obtained was filtered, washed with toluene (10 mL), and the wet solid was dried at 50°C to 55°C under vacuum.
Yield = 19.0 g (75%)
Melting Point = 107°C to 109°C
MS (m/z) = 254
Example 3: Preparation of 5-chloro-N-r(2S)-oxiran-2-ylmethyllthiophene-2-carboxamide (Formula V)
A solution of 5-chloro-N-[(2S)-3-chloro-2-hydroxypropyl]thiophene-2- carboxamide (Formula II - 5.0 g, 0.0196 moles) in methanol (20 mL) was cooled to 0°C to 5°C, and a solution of sodium hydroxide (0.787 g, 0.0196 moles) in deionized water (20 mL) was added at 0°C to 10°C. The mixture was stirred for 5 hours at 0°C to 5°C. The reaction mass was concentrated at 50°C to 55°C under vacuum. The residue obtained was suspended in dichloromethane (30 mL), and the solution was washed with deionized water (35 mL). The organic layer was separated and concentrated under vacuum at 35°C to 40°C to obtain the title compound.
Yield = 3.5 g (80%) Example 4: Preparation of 5-chloro-N-r(2R -2-hvdroxy-3- {r4-(3-oxomorpholin-4-yl phenyll amino }propyHthiophene-2-carboxamide (Formula VII)
4-Aminophenyl morpholinone-3-one (Formula VI - 1.76 g, 0.00914 moles) was added to a solution of 5-chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide (Formula V - 2 g, 0.00919 moles) in ethanol (31.5 mL) and deionized water (3.5 mL) at ambient temperature. The mixture was allowed to heat to 70°C to 75°C and stirred for 4 hours at 70°C to 75°C. The reaction mixture was cooled to 15°C, and the slurry obtained was stirred for 1 hour at 15°C to 20°C. The slurry was filtered and suck dried. The wet solid was dried under vacuum at 40°C to 45°C.
Yield = 2.9 g (77%)
Example 5: Preparation of 5-chloro-N-({(5S)-2-oxo-3-r4-(3-oxomorpholin-4-yl)phenyl1- l,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (rivaroxaban of Formula I)
1 , 1 -Carbonyldiimidazole (0.35 g, 0.00216 moles) was added to a solution of 5- chloro-N- [(2R)-2-hydroxy-3 - { [4-(3 -oxomorpholin-4-yl)phenyl] amino }propyl]thiophene- 2-carboxamide (Formula VII - 0.5 g, 0.00121 moles) in dichloromethane (7.5 mL). The mixture was stirred for 3 hours at 25°C to 30°C. The slurry of the reaction mass was filtered, washed with dichloromethane (2.0 mL), and the wet solid was dried at 40°C to 45°C under vacuum.
Yield = 0.45 g (85%)

Claims

We Claim:
1. A process for the preparation of 5-chloro-N-[(2S)-3-chloro-2- hydroxypropyl]thiophene-2-carboxamide of Formula II,
Figure imgf000019_0001
Formula II
wherein the process comprises treatin a compound of Formula III
Figure imgf000019_0002
Formula III
or a salt thereof with a reactive derivative of a compound of Formula IV.
Figure imgf000019_0003
Formula IV
2. A process for the preparation of rivaroxaban of Formula I,
Figure imgf000019_0004
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000019_0005
Formula III or a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000020_0001
Formula IV
to obtain a com ound of Formula II; and
Figure imgf000020_0002
Formula II
b) converting the compound of Formula II into rivaroxaban.
3. A process for the preparation of rivaroxaban of Formula I,
Figure imgf000020_0003
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000020_0004
Formula III
or a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000020_0005
Formula IV
to obtain a compound of Formula II;
Figure imgf000021_0001
Formula II b) treating the com ound of Formula II
Figure imgf000021_0002
Formula II with a base to obtain a compound of Formula V;
Figure imgf000021_0003
Formula V c) treating the compound of Formula V
Figure imgf000021_0004
Formula V with a compound of Formula VI
Figure imgf000021_0005
Formula VI to obtain a compound of Formula VII; and
Figure imgf000022_0001
Formula VII
d) converting the compound of Formula VII into rivaroxaban.
4. A process for the preparation of rivaroxaban of Formula I,
Figure imgf000022_0002
Formula I
wherein the process comprises:
a) treating a compound of Formula III
Figure imgf000022_0003
Formula III
or a salt thereof with a reactive derivative of a compound of Formula IV
Figure imgf000022_0004
Formula IV
to obtain a com ound of Formula II;
Figure imgf000022_0005
Formula II
b) treating the compound of Formula II
Figure imgf000023_0001
Formula II
with a base to obtain a compound of Formula V; and
Figure imgf000023_0002
Formula V
c) converting the compound of Formula V into rivaroxaban.
5. A process for the preparation of a compound of Formula V,
Figure imgf000023_0003
Formula V
wherein the process comprises treatin a compound of Formula II
Figure imgf000023_0004
Formula II
with a base to obtain the compound of Formula V.
6. The process according to claims 3 to 5, wherein the compound of Formula II is treated with base in a solvent selected from 1 ,4-dioxane, methanol, ethanol, or their mixtures with water.
7. The process according to claims 3 to 6, wherein the base is selected from sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide, potassium hydroxide, or a mixture thereof.
8. The process according to claims 1 to 4, wherein the compound of Formula III is treated with the reactive derivative of the compound of Formula IV in a solvent selected from tetrahydrofuran, toluene, dichloromethane, ethyl acetate, or a mixture thereof.
9. The process according to claims 1 to 4 or 8, wherein the compound of Formula III is treated with the reactive derivative of the compound of Formula IV in the presence of sodium bicarbonate.
10. The process according to claims 1 to 4, 8, or 9, wherein the reactive derivative of the compound of Formula IV is 5-chlorothiophene-2-carbonyl chloride, 5- chlorothiophene-2-carbonyl bromide or 5-chlorothiophene-2-carbonyl iodide.
11. The process according to claim 3, wherein the compound of Formula V is treated with the compound of Formula VI in a solvent selected from ethanol, methanol, tetrahydrofuran, or their mixture with water.
12. The process according to claim 3, wherein the compound of Formula VII is treated with 1 , 1 -carbonyldiimidazole in dichloromethane.
13. A compound of Formula II.
Figure imgf000024_0001
Formula II
PCT/IB2013/053025 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof Ceased WO2013156936A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SG11201406623PA SG11201406623PA (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof
AU2013250801A AU2013250801A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof
US14/394,547 US20150299160A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof
EP13726292.9A EP2838897A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof
IN9450DEN2014 IN2014DN09450A (en) 2012-04-16 2013-04-16

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1174/DEL/2012 2012-04-16
IN1174DE2012 2012-04-16

Publications (1)

Publication Number Publication Date
WO2013156936A1 true WO2013156936A1 (en) 2013-10-24

Family

ID=48539327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/053025 Ceased WO2013156936A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof

Country Status (6)

Country Link
US (1) US20150299160A1 (en)
EP (1) EP2838897A1 (en)
AU (1) AU2013250801A1 (en)
IN (1) IN2014DN09450A (en)
SG (1) SG11201406623PA (en)
WO (1) WO2013156936A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819468A (en) * 2013-12-05 2014-05-28 浙江天宇药业股份有限公司 Synthesis method of Rivaroxaban and intermediate thereof
CN104478820A (en) * 2014-12-22 2015-04-01 杭州瀚康生物医药科技有限公司 Preparation method of rivaroxabanintermediate
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
CN104788444A (en) * 2015-05-12 2015-07-22 浙江天顺生物科技有限公司 Preparation method of rivaroxaban
CN104817550A (en) * 2015-05-26 2015-08-05 山东铂源药业有限公司 Preparation method of rivaroxaban
CN104910141A (en) * 2015-05-12 2015-09-16 浙江天顺生物科技有限公司 Preparation method for Rivaroxaban intermediate 5-chloro-N-(2-oxiranylmethyl)-2-thiophene methanamide

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108707080B (en) * 2018-06-20 2022-01-25 上海圣赢生物科技有限公司 Environment-friendly synthesis method of linezolid and intermediate thereof
CN109400577B (en) * 2019-01-07 2021-01-19 石药集团中奇制药技术（石家庄）有限公司 Rivaroxaban related compound and preparation method and application thereof
CN112110910B (en) * 2019-06-19 2024-03-19 上海特化医药科技有限公司 Method for preparing rivaroxaban intermediate and method for preparing rivaroxaban from rivaroxaban intermediate

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107519A (en) 1997-11-07 2000-08-22 Pharmacia & Upjohn Company Process to produce oxazolidinones
WO2004060887A1 (en) * 2003-01-07 2004-07-22 Bayer Healthcare Ag Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
US20070066615A1 (en) 2003-05-19 2007-03-22 Bayer Heathcare Ag Heterocyclic compounds
DE102007028320A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
WO2009007027A1 (en) * 2007-07-11 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders
US20100120718A1 (en) 2006-11-02 2010-05-13 Bayer Schering Pharma Aktiengesellschaft Combination therapy of substituted oxazolidinones
US20100273789A1 (en) 2007-07-11 2010-10-28 Bayer Schering Pharma Aktiengesellschaft Aminoacyl prodrugs
WO2011098501A1 (en) 2010-02-10 2011-08-18 Sandoz Ag Method for the preparation of rivaroxaban
WO2012092873A1 (en) 2011-01-07 2012-07-12 浙江九洲药业股份有限公司 Synthetic rivaroxaban intermediate and preparation method thereof
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107519A (en) 1997-11-07 2000-08-22 Pharmacia & Upjohn Company Process to produce oxazolidinones
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
WO2004060887A1 (en) * 2003-01-07 2004-07-22 Bayer Healthcare Ag Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide
US8106192B2 (en) 2003-01-07 2012-01-31 Bayer Pharma Aktiengesellschaft Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US20070066615A1 (en) 2003-05-19 2007-03-22 Bayer Heathcare Ag Heterocyclic compounds
US20100120718A1 (en) 2006-11-02 2010-05-13 Bayer Schering Pharma Aktiengesellschaft Combination therapy of substituted oxazolidinones
DE102007028320A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
WO2009007027A1 (en) * 2007-07-11 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders
US20100273789A1 (en) 2007-07-11 2010-10-28 Bayer Schering Pharma Aktiengesellschaft Aminoacyl prodrugs
WO2011098501A1 (en) 2010-02-10 2011-08-18 Sandoz Ag Method for the preparation of rivaroxaban
WO2012092873A1 (en) 2011-01-07 2012-07-12 浙江九洲药业股份有限公司 Synthetic rivaroxaban intermediate and preparation method thereof
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819468A (en) * 2013-12-05 2014-05-28 浙江天宇药业股份有限公司 Synthesis method of Rivaroxaban and intermediate thereof
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
CN104478820A (en) * 2014-12-22 2015-04-01 杭州瀚康生物医药科技有限公司 Preparation method of rivaroxabanintermediate
CN104788444A (en) * 2015-05-12 2015-07-22 浙江天顺生物科技有限公司 Preparation method of rivaroxaban
CN104910141A (en) * 2015-05-12 2015-09-16 浙江天顺生物科技有限公司 Preparation method for Rivaroxaban intermediate 5-chloro-N-(2-oxiranylmethyl)-2-thiophene methanamide
CN104788444B (en) * 2015-05-12 2018-11-06 浙江天顺生物科技有限公司 The preparation method of razaxaban
CN104817550A (en) * 2015-05-26 2015-08-05 山东铂源药业有限公司 Preparation method of rivaroxaban
CN104817550B (en) * 2015-05-26 2017-06-16 山东铂源药业有限公司 A kind of preparation method of razaxaban

Also Published As

Publication number Publication date
IN2014DN09450A (en) 2015-07-17
US20150299160A1 (en) 2015-10-22
EP2838897A1 (en) 2015-02-25
AU2013250801A1 (en) 2014-11-06
SG11201406623PA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
WO2013156936A1 (en) Process for the preparation of rivaroxaban and intermediates thereof
CA2512504C (en) Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
EP2521717B1 (en) Method for the preparation of rivaroxaban
CA2553237C (en) Production method
US9126990B2 (en) Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one
JP2024530111A (en) Process for preparing aficamten
CN114478690B (en) Preparation method of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane derivative
WO2013175431A1 (en) Process for the preparation of rivaroxaban
US9663505B2 (en) Process for the preparation of rivaroxaban
WO2015011617A1 (en) Process for the preparation of rivaroxaban
CN104817550B (en) A kind of preparation method of razaxaban
CN104788361B (en) The synthetic method of the formic acid derivates of 5 azaspiros [2.4] heptane 6
JP2023502123A (en) S1P1 modulator compounds and methods of preparing compounds
CN103265482A (en) Preparation method of bosutinib
CN102939285B (en) Preparation method of 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazole-3-one
CN105175331A (en) Preparation method for EGFR molecule targeting antitumor drug
CN104926807B (en) A kind of razaxaban related substances " diamines " and its synthetic method
CN110498771A (en) A method of preparing the intermediate for disliking La Geli
WO2012041263A2 (en) A method of manufacturing 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-lh-isoindol-l,3(2h)-dione with a high optical purity
EP2895176B1 (en) Rivaroxaban intermediate and preparation thereof
CN113527117A (en) Preparation method of AEEA
CN104961736A (en) Related substance of rivaroxaban--triamine and synthetic methods thereof
CN107382897A (en) A kind of intermediate of betrixaban and its preparation method and application
WO2014020458A1 (en) Improved process for preparation of rivaroxaban
CN113943281B (en) Synthetic method and application of isoxazole pyrimidine derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13726292

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14394547

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013726292

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013726292

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013250801

Country of ref document: AU

Date of ref document: 20130416

Kind code of ref document: A